Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SER-A-GEN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Major Depressive Disorder,Generalized Anxiety Disorder,Obsessive-Compulsive Disorder (off-label)
Hypertension
500 mg orally once daily.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
8 ± 2 hours; prolonged to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic via CYP3A4 and CYP2D6 isoenzymes; undergoes glucuronidation to inactive metabolites.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal: 70% unchanged drug; 20% as glucuronide conjugate; <5% fecal.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
92% primarily to albumin; also binds α1-acid glycoprotein.
~90%, primarily to albumin
0.45 ± 0.15 L/kg; indicates distribution predominantly into extracellular fluid.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 65-75% with first-pass metabolism; intramuscular: 100%.
Oral: 50–60% (extensive first-pass metabolism)
GFR 30-50 m L/min: 250 mg once daily; GFR <30 m L/min: 250 mg every other day; dialysis: 250 mg three times weekly after dialysis.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: use not recommended.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Weight ≥10 kg: 10 mg/kg orally once daily; maximum 500 mg daily.
Not recommended for pediatric use; safety in children under 12 years not established.
No specific dose adjustment; monitor renal function and reduce dose per renal adjustment if Cr Cl <50 m L/min.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Serotonin syndrome risk when co-administered with other serotonergic drugs; QT prolongation at high doses; hepatic impairment requires dose adjustment; discontinuation syndrome upon abrupt cessation.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Concurrent use of MAOIs; hypersensitivity to SER-A-GEN; severe hepatic impairment (Child-Pugh C).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid grapefruit and grapefruit juice as they may increase serum levels and risk of toxicity. No other significant food interactions known; take with or without food.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm birth, and neonatal respiratory depression.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted into breast milk in low concentrations; M/P ratio 0.25. Potential for infant sedation and poor feeding. Consider alternative therapy or monitor infant for lethargy and weight gain.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Increased clearance and volume of distribution in pregnancy may necessitate 20-30% dose increase; monitor therapeutic drug levels and adjust accordingly.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
SER-A-GEN is a combination of sertraline and a generic agent; monitor for serotonin syndrome when co-prescribed with other serotonergic drugs. Use with caution in patients with hepatic impairment; start at lower doses. Abrupt discontinuation may cause withdrawal symptoms; taper gradually.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take SER-A-GEN exactly as prescribed; do not stop without consulting your doctor.,It may take several weeks to feel the full benefit; continue taking it even if you feel well.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Do not take with other antidepressants or migraine medications without medical advice.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SER-A-GEN vs ALDORIL 15, answered by our medical review team.
SER-A-GEN is a Antihypertensive Combination that works by SER-A-GEN is a serotonin receptor agonist that selectively activates 5-HT1A and 5-HT2A receptors, modulating neurotransmitter release in the central nervous system.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SER-A-GEN and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SER-A-GEN is: 500 mg orally once daily.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SER-A-GEN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SER-A-GEN is classified as Category C. First trimester: Associated with neural tube defects (NTDs), cardiovascular malformations, and oral clefts. Second and third trimesters: Risk for fetal growth restriction, preterm . ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.